Research & Development
Diabetes: Page 2
Glucose testing market to reach $27.1B by 2027: Kalorama
With a compound annual growth rate (CAGR) anticipated at 5.9%, the market is expected to reach $27.1 billion by 2027, said the report published by LabPulse.com's sister brand Kalorama Information.
September 18, 2022
Biosensor developer Know Labs goes public on the NYSE
After the close of trading Thursday, the company announced the pricing of an underwritten public offering of 3.6 million shares at $2.00 per share; it granted to the underwriter a 45-day option to purchase up to 540,000 additional shares at the same price.
September 15, 2022
USPSTF: more evidence needed on diabetes screening
The Task Force concluded that more research is needed to recommend for or against screening children and adolescents without signs or symptoms.
September 12, 2022
Long COVID outpaces diabetes in 2022 employer health spending
The firm said that it conducted an extensive study to examine the costs of long COVID and its associated conditions -- breathing abnormalities, malaise and fatigue, cough, throat and chest pain, and respiratory failure.
August 30, 2022
Precision Diabetes, DxGen to launch diabetes analyzer
The analyzer will include hemoglobin A1c, C-reactive protein, and urinary albumin tests, and add other tests later.
August 21, 2022
Renalytix underscores KidneyIntelX clinical results
Specifically, the results show that these physicians understand the value of the test in determining treatment decisions for adults with type 2 diabetes and early chronic kidney disease stages 1 to 3, also known as diabetic kidney disease, the firm said.
August 7, 2022
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
LumiraDx Q4 revenues drop 65% on lower COVID-19 testing
Patients prefer immediate test results, even when the news is bad
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Roche H1 diagnostics revenues up 10% year over year
The firm posted core laboratory revenues of CHF 3.88 billion, up 3% year-over-year from CHF 3.77 billion; point-of-care revenues of CHF 2.61 billion, up 45% year-over-year from CHF 1.80 billion; molecular laboratory revenues of CHF 1.98 billion, down 1% year-over-year from CHF 1.99 billion; diabetes care revenues for CHF 832 million, down 7% year-over-year from CHF 894 million; and pathology laboratory revenues of CHF 652 million, up 11% year-over-year from CHF 590 million.
July 20, 2022
GBS study compares glucose levels in saliva, blood
The developer of a biosensor platform for point-of-care testing said it will now perform statistical analyses of the correlation of glucose levels among the sample types.
July 13, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Abbott to develop new glucose-ketone monitoring system
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation for the device, which will be the same size as the company's FreeStyle Libre 3 sensor, it said.
June 5, 2022
LumiraDx diabetes test receives CE Mark
The LumiraDx HbA1c test is used with the LumiraDx Platform for monitoring individuals with diabetes and provides results in less than seven minutes from sample application. The test is further used as an aid in screening and identifying patients who may be at risk for developing diabetes at the point of care, the company said.
June 1, 2022
COVID-19 testing offers chance for diabetes screening, too
Study investigators hypothesized that they could leverage the existing COVID-19 testing infrastructure to also test for prediabetes and diabetes in a Latinx community that might otherwise face substantial barriers to care engagement.
May 26, 2022
Page 2 of 6